Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough
Source: Streetwise Reports  (9/29/21)
Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial. More >

Nanotech Co.'s Shares Trade Higher After Developing Antimicrobial Coating for PPE
Source: Streetwise Reports  (9/23/21)
ZEN Graphene Solutions Ltd. shares traded 13.5% higher after the company reported it delivered its first revenue-generating shipment of ZENGuard, a patent-pending coating with 99% antimicrobial activity. The first commercial shipment follows the firm's announcement yesterday that Health Canada determined ZENGuard enhanced surgical masks are safe for use by Canadians. More >

Dynavax Shares Shoot Up 30% After Its Partner Clover Biopharma Met All Key Efficacy Endpoints in Ph. 2/3 COVID-19 Vaccine Trial
Source: Streetwise Reports  (9/22/21)
Shares of Dynavax Technologies Corp. established a new 52-week high after the company reported that in the global Phase 2/3 SPECTRA COVID-19 vaccine study its collaborative partner Clover Biopharmaceuticals met all primary and secondary efficacy endpoints. Clover's vaccine, which was developed using Dynavax's CpG 1018 adjuvant, demonstrated 100% efficacy against severe COVID-19 and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2, including the Delta, Gamma, and Mu variants. More >

'Poised for Two Key Readouts in Q1/22' as Biopharma Advances Pipeline
Source: Streetwise Reports  (9/21/21)
Rezolute's two drug candidates, one for congenital hyperinsulinism and the other for diabetic macular edema, are discussed in an H.C. Wainwright & Co. report. More >

Target Price Raised on Biopharma After It Acquires Company, Splits Stock
Source: Streetwise Reports  (9/20/21)
AzurRx BioPharma now has five additional shots on goal "with the imminent full acquisition of just one compound," a ROTH Capital Partners report noted. More >

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study
Source: Streetwise Reports  (9/20/21)
Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients. More >

Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference
Source: Streetwise Reports  (9/18/21)
Innate Pharma S.A. shares traded 38% higher after the company reported its development partner AstraZeneca Plc. reported positive interim results from its Phase 2 COAST Study to the European Society for Medical Oncology Congress. When taken together with durvalumab, monalizumab was shown to improve progression-free survival and objective response rates in patients with unresectable, Stage III non-small cell lung cancer. More >

Leap Therapeutics Shares Skip Higher on Positive Preliminary Data From Gastric Cancer Study
Source: Streetwise Reports  (9/16/21)
Shares of Leap Therapeutics Inc. traded 38% higher after the company reported positive preliminary data from the Phase 2a DisTinGuish Study of DKN-01 plus tislelizumab at the European Society for Medical Oncology Congress. More >

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients
Source: Streetwise Reports  (9/15/21)
ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed with nonalcoholic steatohepatitis. ROTH rates Inventiva a "Buy" with a 12-month price target of €55/share which represents a nearly four-fold increase over the current share price. More >

Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study
Source: Streetwise Reports  (9/15/21)
Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients. More >

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies
Source: Streetwise Reports  (9/14/21)
H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share. More >

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial
Source: Streetwise Reports  (9/13/21)
Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients. More >

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business
Source: Streetwise Reports  (9/8/21)
Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash. Sanofi aims to strengthen its transplant business with the addition of Kadmon's Rezurockâ„¢ (belumosudil), an FDA-approved, first-in-class treatment for patients 12 years and older with chronic graft-versus-host disease. More >

Adaptimmune Partners With Genentech to Develop & Market Cancer-Targeted Allogeneic T-Cell Therapies
Source: Streetwise Reports  (9/7/21)
Adaptimmune Therapeutics Plc. shares traded 33% higher after the firm reported it formed a strategic partnership with Genentech to develop several "off-the-shelf" and advanced personalized cancer-targeting allogeneic T-cell therapies. More >

Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD Tech
Source: Streetwise Reports  (9/4/21)
Shares of Impel NeuroPharma Inc. traded to a new 52-week high after the company reported that the U.S. Food and Drug Administration has approved TRUDHESAâ„¢ (dihydroergotamine mesylate), a patient friendly nasal spray that delivers rapid relief and treatment for acute migraine. More >

Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China
Source: Streetwise Reports  (8/31/21)
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. More >

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline
Source: Streetwise Reports  (8/31/21)
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. More >

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21
Source: Streetwise Reports  (8/30/21)
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. More >

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate
Source: Streetwise Reports  (8/30/21)
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. More >

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments
Source: Streetwise Reports  (8/28/21)
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbodyâ„¢ ISAC programs. More >

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon
Source: Streetwise Reports  (8/24/21)
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." More >

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect
Source: Streetwise Reports  (8/23/21)
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. More >

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher
Source: Streetwise Reports  (8/23/21)
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. More >

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'
Source: Streetwise Reports  (8/23/21)
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. More >

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials
Source: Streetwise Reports  (8/18/21)
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. More >